Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
Tóm tắt
Levodopa is the most effective symptomatic treatment of Parkinson’s disease. However, after an initial period of dramatic benefit, several limitations become apparent including, “dopa resistant” motor symptoms (postural abnormalities, freezing episodes, speech impairment), “dopa resistant” non-motor signs (autonomic dysfunction, mood and cognitive impairment, etc), and/or drug related side effects (especially psychosis, motor fluctuations, and dyskinesias). Motor complications include fluctuations, dyskinesias, and dystonias. They can be very disabling and difficult to treat. Therefore, strategies should ideally be developed to prevent them. Though mechanisms underlying motor complications are only partially understood, recent work has revealed the importance of pulsatile stimulation of postsynaptic dopamine receptors and the disease severity. As a result of intermittent stimulation there occurs a cascade of changes in cell signalling leading to upregulation of the N-methyl-D-aspartate subtype of gamma-aminobutryric acid-ergic neurones. Modified preparations of levodopa (controlled release preparations, liquid levodopa), catecholamine-o-methyltransferase inhibitors, dopamine agonists, amantidine, and various neurosurgical approaches have been used in the prevention and/or treatment of motor complications. Current management of motor complications is less than satisfactory. With better understanding of the pathogenetic mechanisms, it is hoped that future therapeutic strategies will provide a safer and targeted treatment.
Từ khóa
Tài liệu tham khảo
Cotzias, 1967, Aromatic amino acids and modification of parkinsonism, N Engl J Med, 276, 374, 10.1056/NEJM196702162760703
Carlssone, 1957, 3, 4-Dihydroxy-phenylalanine and 5-hydroxytryptaphan as reverie antagonists, Nature, 180, 1200, 10.1038/1801200a0
Ehringer, 1960, Verteilung von Noradrenalin und Dopamin (3-Hydroxy-tyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems, Klin Wochenschr, 38, 1236, 10.1007/BF01485901
Agid, 1999, Members of the Consensus meeting. Levodopa in the treatment of Parkinson’s disease: a consensus meeting, Mov Disord, 14, 911, 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H
Quinn, 1995, Parkinson’s disease—recognition and differential diagnosis, BMJ, 310, 447, 10.1136/bmj.310.6977.447
Barbeau, 1974, The clinical physiology of side effects in long term L-dopa therapy, Adv Neurol, 5, 347
Vaamonde, 2003, Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian patients, Neurologia, 18, 162
Kostic, 2002, The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications, Eur J Neurol, 9, 9, 10.1046/j.1468-1331.2002.00346.x
Horstink, 1990, Severity of Parkinson’s disease as a risk factor for peak dose dyskinesia, J Neurol Neurosurg Psychiatry, 53, 224, 10.1136/jnnp.53.3.224
Nyggard, 1991, Dopa-responsive dystonia: long treatment response and prognosis, Neurology, 41, 174, 10.1212/WNL.41.2_Part_1.174
Mones, 1971, Analysis of L-dopa-induced dyskinesia in 51 patients with parkinsonism, J Neurol Neurosurg Psychiatry, 12, 668, 10.1136/jnnp.34.6.668
Chase, 1973, Levodopa induced dyskinesias. Comparison in parkinsonism-dementia and amyotrophic lateral sclerosis, Arch Neurol, 29, 328, 10.1001/archneur.1973.00490290068008
Schneider, 1989, Levodopa induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage, Pharmacol Biochem Behav, 34, 193, 10.1016/0091-3057(89)90372-9
Boyce, 1990, Nigrostriatal damage is required for induction of dyskinesia by L-dopa in squirrel monkeys, Clin Neuropharmacol, 13, 448, 10.1097/00002826-199010000-00006
Clarke, 1987, Timing of levodopa therapy: evidence from MPTP -treated primates, Lancet, i, 625, 10.1016/S0140-6736(87)90260-1
Fabbrini, 1987, Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease, Ann Neurol, 21, 370, 10.1002/ana.410210409
Nyholm, 2003, Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets, Clin Neuropharmacol, 26, 156, 10.1097/00002826-200305000-00010
Mouradian, 1990, Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease, Ann Neurol, 27, 18, 10.1002/ana.410270105
Priano, 2002, Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson’s disease, Neurol Sci, 23, S99, 10.1007/s100720200088
Rascol, 2000, A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa, N Engl J Med, 342, 1484, 10.1056/NEJM200005183422004
Maratos, 2003, Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus), Exp Neurol, 179, 90, 10.1006/exnr.2002.8055
Marco, 2002, Use of the dopamine agonist cabergoline in the treatment of movement disorders, Expert Opin Pharmacother, 3, 1481, 10.1517/14656566.3.10.1481
Cristina, 2003, High-dose ropinirole in advanced Parkinson’s disease with severe dyskinesias, Clin Neuropharmacol, 26, 146, 10.1097/00002826-200305000-00008
Stocchi, 2002, Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease, Brain, 125, 2058, 10.1093/brain/awf214
Calon, 2002, Levodopa response motor complications—GABA receptors and preproenkephalin expression in human brain, Parkinsonism Relat Disord, 8, 449, 10.1016/S1353-8020(02)00029-9
Oh, 2002, Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson’s disease, Amino Acids, 23, 133, 10.1007/s00726-001-0118-2
Chase, 1998, The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease, Drugs, 55, 1, 10.2165/00003495-199855001-00001
Calon, 2003, Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications, Mov Disord, 18, 241, 10.1002/mds.10343
Blanchet, 1996, Acute pharmacologic blockade of dyskinesias in Parkinson’s disease, Mov Disord, 11, 580, 10.1002/mds.870110516
Verhagen Metman, 2002, Recognition and treatment of response fluctuations in Parkinson’s disease, Amino Acids, 23, 141, 10.1007/s00726-001-0119-1
Allain, 2000, Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. The French Lisuride Study Group, Eur Neurol, 44, 22, 10.1159/000008188
Askmark, 2003, The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption—a nation-wide perspective in Sweden, Parkinsonism Relat Disord, 9, 271, 10.1016/S1353-8020(02)00117-7
Brooks, 2003, Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomized, placebo-controlled, double blind, six-month study, J Neurol Neurosurg Psychiatry, 74, 1071, 10.1136/jnnp.74.8.1071
Sommer, 2002, Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome, Nervenarzt, 73, 761, 10.1007/s00115-002-1354-8
Poewe, 2002, Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a six-month randomized, placebo-controlled, double blind, study in Germany and Austria (Celomen Study), Acta Neurol Scand, 105, 1, 10.1034/j.1600-0404.2002.1o174.x
Olanow, 2000, Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors, Neurology, 55, S72
Rajput, 1997, Amantidine ameliorates levodopa-induced dyskinesia, Neurology, 48, A328
Verhagen Metman, 1997, Amantidine palliates motor response complications in Parkinson’s disease, Ann Neurol, 42, 409
Crosby, 2003, Amantadine for dyskinesia in Parkinson’s disease (Cochrane Review), Cochrane Database Syst Rev, CD003467
Cedarbaum, 1989, A double blind cross over comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson’s disease and fluctuating performance, J Neurol Neurosurg Psychiatry, 52, 207, 10.1136/jnnp.52.2.207
Le Witt, 1989, Controlled release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies, Neurology, 39, 45
Block, 1997, Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson’s disease, Eur Neurol, 37, 23, 10.1159/000117399
Kurth, 1993, Oral levodopa/carbidopa solution versus tablet in Parkinson’s disease with severe fluctuations: a pilot study, Neurology, 43, 1036, 10.1212/WNL.43.5.1036
Ostergaard, 2002, Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson’s disease and motor fluctuations, Mov Disord, 17, 693, 10.1002/mds.10188
The Deep-Brain Stimulation for Parkinson’s Disease Study Group, 2001, Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson’s disease, N Engl J Med, 345, 956, 10.1056/NEJMoa000827
Narabayashi, 1984, Levodopa-induced dyskinesia and thalamotomy, J Neurol Neurosurg Psychiatry, 47, 831, 10.1136/jnnp.47.8.831
Laitinen, 1995, Pallidotomy for Parkinson’s disease, Neurosurg Clin N Am, 6, 105, 10.1016/S1042-3680(18)30479-0
Fox, 2002, Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease, Mov Disord, 17, 1180, 10.1002/mds.10289
Bove, 2002, Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats, Synapse, 46, 251, 10.1002/syn.10112
Oh, 2002, Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models, Exp Neurol, 177, 557, 10.1006/exnr.2002.8009
Djaldetti, 2002, New drugs in the future treatment of Parkinson’s disease, J Neurol, 249, II30